Cargando…

Psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant HepG2 cells

BACKGROUND: Psoralen (PSO), a major active component of Psoralea corylifolia, has been shown to overcome multidrug resistance in cancer. A drug carrier comprising a lipid-monolayer shell and a biodegradable polymer core for sustained delivery and improved efficacy of drug have exhibited great potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Yueling, Cai, Tiange, Callaghan, Richard, Li, Qianwen, Huang, Yinghong, Wang, Bingyue, Huang, Qingqing, Du, Manling, Ma, Qianqian, Chiba, Peter, Cai, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443224/
https://www.ncbi.nlm.nih.gov/pubmed/30988617
http://dx.doi.org/10.2147/IJN.S189924
_version_ 1783407827490963456
author Yuan, Yueling
Cai, Tiange
Callaghan, Richard
Li, Qianwen
Huang, Yinghong
Wang, Bingyue
Huang, Qingqing
Du, Manling
Ma, Qianqian
Chiba, Peter
Cai, Yu
author_facet Yuan, Yueling
Cai, Tiange
Callaghan, Richard
Li, Qianwen
Huang, Yinghong
Wang, Bingyue
Huang, Qingqing
Du, Manling
Ma, Qianqian
Chiba, Peter
Cai, Yu
author_sort Yuan, Yueling
collection PubMed
description BACKGROUND: Psoralen (PSO), a major active component of Psoralea corylifolia, has been shown to overcome multidrug resistance in cancer. A drug carrier comprising a lipid-monolayer shell and a biodegradable polymer core for sustained delivery and improved efficacy of drug have exhibited great potential in efficient treatment of cancers. METHODS: The PSO-loaded lipid polymer hybrid nanoparticles were prepared and characterized. In vitro cytotoxicity assay, cellular uptake, cell cycle analysis, detection of ROS level and mitochondrial membrane potential (ΔΨm) and western blot were performed. RESULTS: The P-LPNs enhanced the cytotoxicity of doxorubicin (DOX) 17-fold compared to free DOX in multidrug resistant HepG2/ADR cells. Moreover, P-LPNs displayed pro-apoptotic activity, increased levels of ROS and depolarization of ΔΨm. In addition, there were no signifi-cant effects on cellular uptake of DOX, cell cycle arrest, or the expression of P-glycoprotein. Mechanistic studies suggested that P-LPNs enhanced DOX cytotoxicity by increased release of cytochrome c and enhanced caspase3 cleavage, causing apoptosis in HepG2/ADR cells. CONCLUSION: The lipid-polymer hybrid nanoparticles can be considered a powerful and promising drug delivery system for effective cancer chemotherapy.
format Online
Article
Text
id pubmed-6443224
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-64432242019-04-15 Psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant HepG2 cells Yuan, Yueling Cai, Tiange Callaghan, Richard Li, Qianwen Huang, Yinghong Wang, Bingyue Huang, Qingqing Du, Manling Ma, Qianqian Chiba, Peter Cai, Yu Int J Nanomedicine Original Research BACKGROUND: Psoralen (PSO), a major active component of Psoralea corylifolia, has been shown to overcome multidrug resistance in cancer. A drug carrier comprising a lipid-monolayer shell and a biodegradable polymer core for sustained delivery and improved efficacy of drug have exhibited great potential in efficient treatment of cancers. METHODS: The PSO-loaded lipid polymer hybrid nanoparticles were prepared and characterized. In vitro cytotoxicity assay, cellular uptake, cell cycle analysis, detection of ROS level and mitochondrial membrane potential (ΔΨm) and western blot were performed. RESULTS: The P-LPNs enhanced the cytotoxicity of doxorubicin (DOX) 17-fold compared to free DOX in multidrug resistant HepG2/ADR cells. Moreover, P-LPNs displayed pro-apoptotic activity, increased levels of ROS and depolarization of ΔΨm. In addition, there were no signifi-cant effects on cellular uptake of DOX, cell cycle arrest, or the expression of P-glycoprotein. Mechanistic studies suggested that P-LPNs enhanced DOX cytotoxicity by increased release of cytochrome c and enhanced caspase3 cleavage, causing apoptosis in HepG2/ADR cells. CONCLUSION: The lipid-polymer hybrid nanoparticles can be considered a powerful and promising drug delivery system for effective cancer chemotherapy. Dove Medical Press 2019-03-27 /pmc/articles/PMC6443224/ /pubmed/30988617 http://dx.doi.org/10.2147/IJN.S189924 Text en © 2019 Yuan et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Yuan, Yueling
Cai, Tiange
Callaghan, Richard
Li, Qianwen
Huang, Yinghong
Wang, Bingyue
Huang, Qingqing
Du, Manling
Ma, Qianqian
Chiba, Peter
Cai, Yu
Psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant HepG2 cells
title Psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant HepG2 cells
title_full Psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant HepG2 cells
title_fullStr Psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant HepG2 cells
title_full_unstemmed Psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant HepG2 cells
title_short Psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant HepG2 cells
title_sort psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant hepg2 cells
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443224/
https://www.ncbi.nlm.nih.gov/pubmed/30988617
http://dx.doi.org/10.2147/IJN.S189924
work_keys_str_mv AT yuanyueling psoralenloadedlipidpolymerhybridnanoparticlesenhancedoxorubicinefficacyinmultidrugresistanthepg2cells
AT caitiange psoralenloadedlipidpolymerhybridnanoparticlesenhancedoxorubicinefficacyinmultidrugresistanthepg2cells
AT callaghanrichard psoralenloadedlipidpolymerhybridnanoparticlesenhancedoxorubicinefficacyinmultidrugresistanthepg2cells
AT liqianwen psoralenloadedlipidpolymerhybridnanoparticlesenhancedoxorubicinefficacyinmultidrugresistanthepg2cells
AT huangyinghong psoralenloadedlipidpolymerhybridnanoparticlesenhancedoxorubicinefficacyinmultidrugresistanthepg2cells
AT wangbingyue psoralenloadedlipidpolymerhybridnanoparticlesenhancedoxorubicinefficacyinmultidrugresistanthepg2cells
AT huangqingqing psoralenloadedlipidpolymerhybridnanoparticlesenhancedoxorubicinefficacyinmultidrugresistanthepg2cells
AT dumanling psoralenloadedlipidpolymerhybridnanoparticlesenhancedoxorubicinefficacyinmultidrugresistanthepg2cells
AT maqianqian psoralenloadedlipidpolymerhybridnanoparticlesenhancedoxorubicinefficacyinmultidrugresistanthepg2cells
AT chibapeter psoralenloadedlipidpolymerhybridnanoparticlesenhancedoxorubicinefficacyinmultidrugresistanthepg2cells
AT caiyu psoralenloadedlipidpolymerhybridnanoparticlesenhancedoxorubicinefficacyinmultidrugresistanthepg2cells